AbbVie Inc. ( ABBV ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena Sobieszczyk Presentation Operator Okay, everyone, if we can wrap up our conversations so that we can get started and come to the main room. So our final panel today is about vaccines.
The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction.
AbbVie presents a bullish outlook supported by positive earnings, a strong dividend, and robust technical indicators. ABBV beat Q3 earnings and revenue expectations, raised full-year EPS guidance, and boasts a promising drug pipeline with strong Skyrizi and Rinvoq sales. Technically, ABBV trades above its 30-week EMA, shows bullish momentum, increasing institutional volume, and has outperformed the S&P 500 this year.
| Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | XMEX Exchange | US00287Y1091 ISIN |
| US Country | 55,000 Employees | 16 Jan 2026 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.